Results for tag: "VRSA Infection Drug"

The VRSA Infection Drug market is a subset of the larger Infectious Diseases Drugs market. VRSA stands for Vancomycin-Resistant Staphylococcus Aureus, a type of bacteria that is resistant to antibiotics. VRSA infections are becoming increasingly common, and the need for effective treatments is growing. VRSA Infection Drugs are designed to target and treat this type of infection. These drugs are typically administered intravenously, and may be used in combination with other antibiotics. The VRSA Infection Drug market is highly competitive, with many companies developing and marketing treatments. Some of the major players in the market include Merck & Co., Pfizer, GlaxoSmithKline, AstraZeneca, and Novartis. Other companies, such as Allergan, Sanofi, and Johnson & Johnson, are also active in the market. Show Less Read more